Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19.
TOKYO, April 15, 2020 —
FUJIFILM Corporation (President: Kenji Sukeno) has announced that
it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for treating patients with COVID-19.
To further boost the supply of Avigan,
Fujifilm is allocating additional capacity at its FUJIFILM Wako Pure Chemical Co., Ltd. facility in Japan, for production of pharmaceutical intermediates used to manufacture Avigan.
In addition,
Fujifilm has established
strategic partnerships with domestic and overseas companies for various manufacturing processes to source raw materials and pharmaceutical substances.
Fujifilm expects to
progressively increase the production of Avigan up to 100,000 treatment courses* by July 2020, approximately 2.5 times more
compared to the beginning of March, when the company first began its current production run.
In addition,
Fujifilm plans to further accelerate production up to 300,000 treatment courses* by September 2020.
Fujifilm Global